Research
Hormonal
Discontinuation of incretin agonists (GLP-1/GIP) leads to significant weight regain (approx. two-thirds of lost weight) within weeks, indicating that current pharmacological efficacy is not sustainable without continuous treatment.
Current GLP-1 and GIP medications are not a one-time fix for obesity. If you stop taking them, you will likely regain most of the weight you lost. This suggests that obesity management with these drugs is a long-term commitment, similar to other chronic conditions, and requires ongoing medical supervision and cost consideration.
GoodRefutesHIGH confidence
when incretin’s manipulation of neuronal pathways is terminated, approximately 2/3 of the lost weight was regained [25,51].
Why this rating
Based on multiple randomized controlled trials (STEP-1 extension, SURMOUNT-4) showing consistent weight regain post-cessation.
Source
Does Incretin Agonism Have Sustainable Efficacy?
Sok‐Ja Janket et al. · Cells · 2024
DOI 10.3390/cells13221842
narrative_reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term use of incretin agonists shows attenuated efficacy over time, with weight loss and HbA1c improvements diminishing significantly in the 3rd to 7th year of treatment.Moderate
- Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →